BRAINSTORM CELL THERAPEUTICS INC. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$3.85 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2026-08-14
- BRAINSTORM CELL THERAPEUTICS INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$3.85M.
- BRAINSTORM CELL THERAPEUTICS INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$2.13M.
- BRAINSTORM CELL THERAPEUTICS INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$2.43M.
- BRAINSTORM CELL THERAPEUTICS INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$2.11M.
- BRAINSTORM CELL THERAPEUTICS INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2025 was -$10.31M.
- BRAINSTORM CELL THERAPEUTICS INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was -$11.62M.
- BRAINSTORM CELL THERAPEUTICS INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was -$17.19M.
- BRAINSTORM CELL THERAPEUTICS INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was -$24.28M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$3.85M 10-Q · filed 2026-08-14 | -$5.98M 10-Q · filed 2026-08-14 | -$8.42M derived: sum of 3 quarters · filed 2026-08-14 | -$10.52M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2026-03-31 | -$2.13M 10-Q · filed 2026-05-15 | -$4.56M derived: sum of 2 quarters · filed 2026-05-15 | -$6.67M derived: sum of 3 quarters · filed 2026-05-15 | -$9.57M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-12-31 | -$2.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$4.54M derived: sum of 2 quarters · filed 2026-03-31 | -$7.44M derived: sum of 3 quarters · filed 2026-08-14 | -$10.31M 10-K · filed 2026-03-31 | ||
| 2025-09-30 | -$2.11M 10-Q · filed 2025-11-14 | -$5.01M derived: sum of 2 quarters · filed 2026-08-14 | -$7.87M 10-Q · filed 2025-11-14 | -$10.85M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-06-30 | -$2.90M 10-Q · filed 2026-08-14 | -$5.77M 10-Q · filed 2026-08-14 | -$8.74M derived: sum of 3 quarters · filed 2026-08-14 | -$11.45M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-03-31 | -$2.86M 10-Q · filed 2026-05-15 | -$5.84M derived: sum of 2 quarters · filed 2026-05-15 | -$8.54M derived: sum of 3 quarters · filed 2026-05-15 | -$11.09M derived: sum of 4 quarters · filed 2026-05-15 | ||
| 2024-12-31 | -$2.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$5.68M derived: sum of 2 quarters · filed 2026-03-31 | -$8.22M derived: sum of 3 quarters · filed 2026-03-31 | -$11.62M 10-K · filed 2026-03-31 | ||
| 2024-09-30 | -$2.71M 10-Q · filed 2025-11-14 | -$5.25M derived: sum of 2 quarters · filed 2025-11-14 | -$8.65M 10-Q · filed 2025-11-14 | -$14.23M derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2024-06-30 | -$2.54M 10-Q · filed 2025-08-14 | -$5.94M 10-Q · filed 2025-08-14 | -$11.52M derived: sum of 3 quarters · filed 2025-08-14 | -$12.75M derived: sum of 4 quarters · filed 2025-08-14 | ||
| 2024-03-31 | -$3.40M 10-Q · filed 2025-05-15 | -$8.98M derived: sum of 2 quarters · filed 2025-05-15 | -$10.21M derived: sum of 3 quarters · filed 2025-05-15 | -$15.53M derived: sum of 4 quarters · filed 2025-05-15 | ||
| 2023-12-31 | -$5.58M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$6.80M derived: sum of 2 quarters · filed 2025-03-31 | -$12.13M derived: sum of 3 quarters · filed 2025-03-31 | -$17.19M 10-K · filed 2025-03-31 | ||
| 2023-09-30 | -$1.23M 10-Q · filed 2024-11-14 | -$6.55M derived: sum of 2 quarters · filed 2024-11-14 | -$11.61M 10-Q · filed 2024-11-14 | -$16.63M derived: sum of 4 quarters · filed 2024-11-14 | ||
| 2023-06-30 | -$5.33M 10-Q · filed 2024-08-14 | -$10.39M 10-Q · filed 2024-08-14 | -$15.41M derived: sum of 3 quarters · filed 2024-08-14 | -$22.26M derived: sum of 4 quarters · filed 2024-08-14 | ||
| 2023-03-31 | -$5.06M 10-Q · filed 2024-05-14 | -$10.08M derived: sum of 2 quarters · filed 2024-05-14 | -$16.93M derived: sum of 3 quarters · filed 2024-05-14 | -$23.98M derived: sum of 4 quarters · filed 2024-05-14 | ||
| 2022-12-31 | -$5.02M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$11.88M derived: sum of 2 quarters · filed 2024-04-01 | -$18.92M derived: sum of 3 quarters · filed 2024-04-01 | -$24.28M 10-K · filed 2024-04-01 | ||
| 2022-09-30 | -$6.86M 10-Q · filed 2023-11-14 | -$13.90M derived: sum of 2 quarters · filed 2023-11-14 | -$19.26M 10-Q · filed 2023-11-14 | -$25.45M derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2022-06-30 | -$7.04M 10-Q · filed 2023-08-14 | -$12.40M 10-Q · filed 2023-08-14 | -$18.59M derived: sum of 3 quarters · filed 2023-08-14 | -$23.93M derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | -$5.36M 10-Q · filed 2023-05-15 | -$11.55M derived: sum of 2 quarters · filed 2023-05-15 | -$16.89M derived: sum of 3 quarters · filed 2023-05-15 | -$23.37M derived: sum of 4 quarters · filed 2023-05-15 | ||
| 2021-12-31 | -$6.19M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$11.53M derived: sum of 2 quarters · filed 2023-03-30 | -$18.01M derived: sum of 3 quarters · filed 2023-03-30 | -$24.46M 10-K · filed 2023-03-30 | ||
| 2021-09-30 | -$5.34M 10-Q · filed 2022-11-14 | -$11.82M derived: sum of 2 quarters · filed 2022-11-14 | -$18.27M 10-Q · filed 2022-11-14 | -$30.30M derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2021-06-30 | -$6.49M 10-Q · filed 2022-08-15 | -$6.27M 10-Q · filed 2021-08-05 | -$13.15M 10-Q · filed 2022-08-15 | -$12.93M 10-Q · filed 2021-08-05 | -$24.96M derived: sum of 3 quarters · filed 2022-08-15 | -$29.45M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | -$6.66M 10-Q · filed 2022-05-16 | -$18.48M derived: sum of 2 quarters · filed 2022-05-16 | -$22.96M derived: sum of 3 quarters · filed 2022-05-16 | -$30.36M derived: sum of 4 quarters · filed 2022-05-16 | ||
| 2020-12-31 | -$11.81M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | -$16.30M derived: sum of 2 quarters · filed 2022-03-28 | -$23.70M derived: sum of 3 quarters · filed 2022-03-28 | -$31.81M 10-K · filed 2022-03-28 | ||
| 2020-09-30 | -$4.49M 10-Q · filed 2021-11-15 | -$11.88M derived: sum of 2 quarters · filed 2021-11-15 | -$20.00M 10-Q · filed 2021-11-15 | -$27.72M derived: sum of 4 quarters · filed 2021-11-15 | ||
| 2020-06-30 | -$7.39M 10-Q · filed 2021-08-05 | -$15.51M 10-Q · filed 2021-08-05 | -$23.23M derived: sum of 3 quarters · filed 2021-08-05 | -$28.86M derived: sum of 4 quarters · filed 2021-08-05 | ||
| 2020-03-31 | -$8.14M 10-Q · filed 2021-04-26 | -$8.11M 10-Q · filed 2020-05-07 | -$15.84M derived: sum of 2 quarters · filed 2021-04-26 | -$21.47M derived: sum of 3 quarters · filed 2021-04-26 | -$26.37M derived: sum of 4 quarters · filed 2021-04-26 | |
| 2019-12-31 | -$7.69M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-04 | -$13.33M derived: sum of 2 quarters · filed 2021-02-04 | -$18.23M derived: sum of 3 quarters · filed 2021-02-04 | -$23.25M 10-K · filed 2021-02-04 | ||
| 2019-09-30 | -$5.63M 10-Q · filed 2020-10-15 | -$10.53M derived: sum of 2 quarters · filed 2020-10-15 | -$15.56M 10-Q · filed 2020-10-15 | -$20.94M derived: sum of 4 quarters · filed 2020-10-15 | ||
| 2019-06-30 | -$4.90M 10-Q · filed 2020-08-05 | -$9.93M 10-Q · filed 2020-08-05 | -$15.31M derived: sum of 3 quarters · filed 2020-08-05 | -$18.49M derived: sum of 4 quarters · filed 2020-08-05 | ||
| 2019-03-31 | -$5.03M 10-Q · filed 2020-05-07 | -$10.41M derived: sum of 2 quarters · filed 2020-05-07 | -$13.59M derived: sum of 3 quarters · filed 2020-05-07 | |||
| 2018-12-31 | -$5.38M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-18 | -$8.56M derived: sum of 2 quarters · filed 2020-02-18 | -$13.95M 10-K · filed 2020-02-18 | |||
| 2018-09-30 | -$3.18M 10-Q · filed 2019-11-14 | -$8.56M 10-Q · filed 2019-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |